Polygenic associations and causal inferences between serum immunoglobulins and amyotrophic lateral sclerosis

Xu Chen[1,2]*, Xiaojun Shen[2], Xuzhuo Zhang[1], Yiqiang Zhan[3,4] and Fang Fang[4]

[1]Department of Central Laboratory, Baoan Women's and Children's Hospital, Shenzhen University, Shenzhen, China.

[2]Institute of Maternal-Fetal Medicine, Baoan Women's and Children's Hospital, Shenzhen University, Shenzhen, China.

[3]German Center for Neurodegenerative Diseases (DZNE), Ulm, Germany.

[4]Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

Correspondence:

Dr. Xu Chen. Department of Central Laboratory, Baoan Women's and Children's Hospital, Shenzhen University, 56 YuLv Road, Shenzhen 518100, China. Phone: +86-15989385199; Email: dr.xuchen@outlook.com

Abstract

Chronic inflammation might contribute to the development of amyotrophic lateral sclerosis (ALS), the relationship between serum immunoglobulins and risk of ALS remains however unclear. In order to overcome limitations like reverse causation and residual confounding commonly seen in the observational studies, we applied molecular epidemiological analyses to examine the polygenic and causal associations between serum immunoglobulins and ALS. Summary statistics from the large-scale genome-wide association studies (GWAS) among European ancestry populations (~15000 individuals for serum immunoglobulins, and more than 36000 individuals for ALS) were accessed from different consortia. The relationships between three types of serum immunoglobulins (IgA, IgM, and IgG) and ALS were investigated in a discovery phase and then in a replication phase. Polygenic risk score (PRS) analysis was performed with PRSice package to test the polygenic association, and Mendelian randomization (MR) analysis was performed with TwoSampleMR package to infer the causality. An inverse polygenic association was discovered between IgA and ALS as well as between IgM and ALS. Such associations were however not replicated using a larger GWAS of ALS, and no causal association was observed for either IgA-ALS or IgM-ALS. A positive polygenic association was both discovered [odds ratio (OR) = 1.18, 95% confidence interval (CI): 1.12-1.25, $P=5.9\times10^{-7}$] and replicated (OR=1.13, 95% CI: 1.06-1.20, P=0.001) between IgG and ALS. A causal association between IgG and ALS was also suggested in both the discovery (OR=1.06, 95%CI: 1.02-1.10, P=0.009) and replication (OR=1.07, 95%CI: 0.90-1.24, P=0.420) analyses, although the latter was not statistically significant. This study suggests a shared polygenic risk between serum IgG (as a biomarker for chronic inflammation) and ALS.

Keywords

Immunoglobulins, Amyotrophic lateral sclerosis, Polygenic risk score, Causal inference, Mendelian randomization

43 ## Introduction

44 Amyotrophic lateral sclerosis (ALS) is a relatively rare but fatal neurodegenerative disease. Chronic
45 inflammation and altered immune responses have been suggested to contribute to the pathogenesis
46 of ALS [1]. The relationship between serum immunoglobulins, as known biomarkers for
47 inflammation and immune responses, and risk of ALS remains however unclear. In a previous study
48 [2], we did not find a statistically significant positive association between immunoglobulin G (IgG)
49 and risk of ALS [hazard ratio=1.04, 95% confidence interval (CI): 0.89-1.22; per 2.99 g/L increase
50 of IgG]. In the same study, we also found that during the 20 years before diagnosis, patients with
51 ALS had more rapidly declining levels of IgG compared to others. We speculate that the noted lack
52 of association between IgG and ALS might be attributable to both a real positive association
53 between IgG and ALS (i.e., higher levels of IgG lead to higher risk of ALS) and reverse causation
54 (i.e., ALS results in declined levels of IgG). In addition to reverse causation, observational studies
55 are also prone to other systemic errors, which collectively make it often difficult to infer causality
56 for noted associations [3].
57
58 By using the summary statistics from large-scale genome-wide association studies (GWAS),
59 polygenic risk score (PRS) and Mendelian randomization (MR) analyses have added novel evidence
60 to support polygenic and causal relationships between several traits and ALS, corroborating
61 importantly findings from previous observational studies [4-6]. In this study, we used GWAS
62 summary statistics to assess the associations of genetically predicted levels of immunoglobulins with
63 the genetically predicted risk of ALS, and to test whether such associations are causal. Since IgG is a
64 biomarker for chronic inflammation, we hypothesized that there is a positive and causal relationship
65 between IgG and ALS. We additionally studied another two serum immunoglobulins (IgA and IgM,
66 two biomarkers that have rarely been studied in ALS) to assess the specificity of the IgG result.
67
68

69 ## Methods

70 ### Summary statistics

71 We used publicly available summary statistics of several GWAS within the European ancestry
72 population in this study. GWAS of serum immunoglobulins (IgA, IgM, and IgG) were conducted
73 among ~15000 individuals (from Iceland and Sweden), from which single nucleotide

74 polymorphisms (SNPs) with the association P-values $<1.0\times10^{-6}$ were available [7]. GWAS summary
75 statistics of ALS were obtained from two studies (available in the IEU GWAS database;
76 https://gwas.mrcieu.ac.uk, ID for ALS_2016: ieu-a-1085; ID for ALS_2018: ebi-a-GCST005647). In
77 the discovery analysis, summary statistics of ALS (ALS_2016) were obtained from a GWAS
78 performed among 36052 individuals (including 12577 patients with ALS and 23475 controls) by the
79 Project MinE group [8]. In the replication analysis, summary statistics of ALS (ALS_2018) were
80 obtained from a meta-analysis incorporating the results from ALS_2016 and another GWAS
81 including 40598 individuals (8229 patients with ALS and 32369 controls) [9]. Because we only used
82 GWAS summary statistics rather than individual-level data in this study, participant inform consent
83 and ethical review permit were waived according to the ethical review board of Shenzhen Baoan
84 Women's and Children's Hospital.
85
86 Using IgA, IgM, and IgG as the exposures (base traits) and ALS as the outcome (target trait), the
87 polygenic and causal associations of six exposure-outcome pairs (three in the discovery analysis and
88 three in the replication analysis) were investigated by PRS and MR analyses, respectively. Because
89 the values of immunoglobulins were standardized in the GWAS, we estimated accordingly odds
90 ratio (OR) per standard deviation of genetically predicted level for each type of immunoglobulin in
91 the present study.
92

93 ## PRS analyses

94 Polygenic associations were investigated by PRS analyses in Linux with PRSice package (version
95 1.25) [10]. For the summary statistics of each exposure, correlated SNPs were pruned by linkage
96 disequilibrium (LD) clumping with default parameter settings. Genotypes of the HapMap_ceu_all
97 (release 22, 60 individuals, 3.96 million SNPs) were used as the reference panel, clumping threshold
98 p1=p2=0.5, LD threshold $r^2=0.05$, and the distance threshold of 300Kb. Independent SNPs were then
99 extracted and included in 100000 quantiles with gradually increasing P-value thresholds (P_T, ranging
100 from 0 to 1.0×10^{-6}, in steps of 1.0×10^{-11} per quantile). The P_T of the quantile that explained the
101 largest variance of the target was defined as the best-fitted P_T.
102

103 ## MR analyses

104 Utilizing the instrumental variable (IV) methods (Figure 1), MR analyses were performed in R
105 (version 3.6.1) with TwoSampleMR package (version 0.5.2) [11]. Causal inference by MR analysis
106 requires three basic assumptions: 1) relevance, i.e., IVs have causal effects on the exposure (e.g.,
107 IgG); 2) exclusion restriction, i.e., IVs affect the outcome (e.g., ALS), only through the exposure;
108 and 3) exchangeability or independence, i.e., no common causes exist between IVs and the outcome
109 [12]. Lead SNPs from the genetic loci reported to be associated with each exposure were extracted
110 from the GWAS of immunoglobulins [7]. The associations of the SNPs with other traits
111 (associations with a P-value $<5\times10^{-8}$) were checked in GWAS Catalog (https://www.ebi.ac.uk/gwas)
112 and excluded, leaving independent lead SNPs after LD clumping as the IVs (Table 1). The causal
113 relationship of each exposure-outcome pair was primarily examined by the inverse variance
114 weighted (IVW) method and complemented with another four methods (MR Egger regression,
115 weighted median, simple and weighted mode) as sensitivity analyses.
116
117
118 **Results**
119 PRS results between serum immunoglobulins and ALS were presented in Figure 2, which including
120 10 out of 100000 quantiles in discovery and replication phases, estimates of the best-fitted quantiles
121 were summarized in Table 2. Inverse polygenic associations were discovered for IgA-ALS and IgM-
122 ALS, neither of the associations was however replicated. A positive polygenic association between
123 IgG and ALS was found both in the discovery and replication analyses, the OR was 1.18 (95% CI:
124 1.12-1.25, $P=5.9\times10^{-7}$) in the discovery analysis and 1.13 (95%CI: 1.06-1.20, P=0.001) in the
125 replication analysis.
126
127 MR results using different methods to infer the causality between serum immunoglobulins and ALS
128 were presented in Figure 3 and summarized in Table 3, respectively. Among these five MR methods,
129 standard error of estimate from IVW method was the smallest (Table 3), while the MR Egger
130 estimates were less precise (with the largest standard error), because the MR Egger method allows
131 variants to have pleiotropic effects. However, causal association was not found for either IgA-ALS
132 or IgM-ALS, regardless of the use of MR methods. For IgG-ALS, a statistically significant causal
133 association was found in the discovery analysis (OR=1.06, 95% CI: 1.02-1.10, P=0.009). A causal

positive association was also suggested in the replication analysis, although not statistically significant (OR=1.07, 95%CI: 0.90-1.24, P=0.420).

Discussion

Based on summary statistics data from large-scale GWAS of immunoglobulins (IgA, IgM, IgG) and ALS, our PRS analyses provided new evidence supporting a polygenic association between IgG and ALS. The MR analyses suggested potentially causal association between IgG and ALS, but it didn't reach statistical significance in the replication phase. The inconsistence of MR estimates in discovery and replication phases probably due to weak instrument bias, population stratification or other confounding.

Accumulating evidence supports that inflammation and altered immune responses are involved in the different phases of ALS [13]. Physiological barriers (e.g., blood-brain barrier) and innate immunity cells (e.g., macrophages) are fundamental in the maintenance and modulation of the central nervous system, whereas chronic inflammation might lead to dysfunction of the neurons [14]. B cells play important roles in adaptive immunity, through producing immunoglobulins and presenting antigens to T cells [15]. IgA constitutes 10-20% of serum immunoglobulins and is mainly involved in the mucosal immune response. IgM constitutes 5-10% of serum immunoglobulins and is the earliest released antibody during adaptive immune response. IgG constitutes ~75% of serum immunoglobulins and can be transmitted through placental and blood-brain barriers [16].

Several studies have indicated a link between IgG and ALS. Deposit of IgG has been found in the spinal cord and motor cortex of some ALS patients [17]. Prevalence of serum monoclonal immunoglobulins (60%, including 44% IgG and 16% IgM) was found to be higher among ALS patients than that of the control group (13%) [18]. High levels of 20 IgG antibodies were also found to help diagnose ALS cases [19]. In our previous cohort study including more than half a million participants with >20 years of follow-up, we found that per 2.99 g/L increase of IgG levels in blood, there was a 4% increased risk of ALS, although the association was not statistically significant [2]. The lack of statistical significance might be multifactorial, including first a potentially real positive association between IgG and ALS risk, a lack of statistical power due to the relatively small number

165 of ALS cases identified (N=152), and also reverse causation (i.e., patients with ALS had more
166 rapidly declining IgG levels, compared to individuals not developing ALS, during the 20 years
167 before ALS diagnosis). However, because genotypes are determined at birth and unchangeable
168 during the life course, our results about a potentially causal relationship between genetically
169 predicted IgG level and genetically predicted ALS risk are unlikely to be dependent on early or late
170 stage of ALS.
171
172 By using summary statistics from several large-scale GWAS, in the present study, we identified a
173 statistically significant positive polygenic association between IgG and ALS in both the discovery
174 and replication analyses. The association is further suggested to be causal in the MR analysis.
175 Although statistically significant result was only obtained in the discovery analysis, similar point
176 estimate was noted in the replication analysis. The differences between the discovery (ALS_2016)
177 and replication (ALS_2018) samples might have contributed to the lack of statistical significance in
178 the replication analysis. For instance, in the discovery GWAS (ALS_2016), patients with ALS and
179 controls were matched for age, sex, and geographic regions, whereas more than 50% of participants
180 in the replication GWAS (ALS_2018) were only matched for race/ethnicity.
181
182 In contrast to IgG, no clear polygenic association nor causal relationship was noted for IgA-ALS and
183 IgM-ALS. A recent observational study, including 489 patients with ALS and 17475 neurologically
184 healthy controls, also failed to detect an association between total serum IgA and ALS [20]. The
185 different result pattern between IgA, IgM and IgG might be partly explained by the fact that IgG is a
186 biomarker for chronic inflammation and bypasses the blood-brain-barrier, which might be more
187 relevant for neurodegenerative diseases including ALS, compared to the other immunoglobulins [21].
188 Besides PRS analyses, we could not perform alternative approaches to test the association between
189 IgG levels and ALS, which could be a potential source for bias. Furthermore, other sensitivity
190 analyses are required to confirm the association between IgG and ALS.
191
192 Even though we used the latest and largest GWAS of immunoglobulins, only two independent SNPs
193 could be selected as IVs for IgG. As a result, we could only use IVW methods in the MR analysis.
194 According to the current GWAS Catalog, no genome-wide significant association was identified
195 between the two IVs of IgG and other non-ALS traits. Interestingly, the two genes near these two

196 IVs are both biologically related to immune responses, neuroinflammation, and neurodegeneration.
197 Genetic variant rs7554873 is close to the *FCGR2B* (Fc fragment of IgG receptor IIb) gene on
198 chromosome 1. Protein FcγRIIB encoded by *FCGR2B* gene is a low-affinity receptor for the Fc
199 region of IgG. FcγRIIB involves in the regulation of antibodies produced by B-cells and in the
200 phagocytosis of immune complexes, it is also reported to mediate the inhibitory effect of aggregated
201 α-synuclein on microglial phagocytosis [22]. Genetic variant rs2133037 is close to the HLA-DQB1
202 (major histocompatibility complex, class II, DQ beta 1) gene on chromosome 6. Its encoded protein
203 HLA-DQB1 is also reported to be associated with immunity and neuronal survival [23].
204
205 In this study, we had only access to GWAS summary statistics data when testing the polygenic and
206 causal relationship between serum immunoglobulins (IgA, IgM, IgG) and ALS. Using a Mendelian
207 randomization analysis, our study is less prone to methodological limitations commonly seen in
208 observational studies such as confounding and reverse causation. Future studies with individual
209 genotype data are warranted in further understanding the roles of other factors (such as age, sex,
210 ethnicity, etc.) in the link between different immunoglobulins (especially IgG) and ALS. More
211 importantly, to further confirm the causal association between IgG and ALS, it should remove the
212 possibility that IgG is a biomarker of ALS rather than a risk factor of ALS. The co-localization
213 analysis for each instrumental variable of IgG might also be helpful to identify if the causal
214 association is driven by common causal genetic variants between IgG and ALS.
215
216 Further, to test whether chronic inflammation is indeed a mechanism linking together IgG and ALS,
217 the role of IgG on other diseases (both diseases with a known link with chronic inflammation and
218 diseases without such a link) needs to be studied. Finally, as high levels of IgG antibodies were
219 suggested to improve the diagnosis of ALS [19], the potential use of IgG measurement in clinical
220 diagnosis of ALS needs to be further examined.
221
222
223 **Conclusions**
224 In conclusion, our study suggests a shared polygenic risk between serum IgG and ALS. The
225 causality between IgG and ALS needs to be further validated when more instrumental variables are
226 available and when different methods of causal inference are possible to use.

227
228
229 **List of abbreviations**

230 ALS: Amyotrophic lateral sclerosis; Ig: immunoglobulin; CI: confidence interval; GWAS: genome-
231 wide association study; PRS: polygenic risk score; MR: Mendelian randomization; SNP: single
232 nucleotide polymorphism; OR: odds ratio; LD: linkage disequilibrium; IVW: inverse variance
233 weighted; FCGR2B: Fc fragment of IgG receptor IIb; HLA-DQB1: Major histocompatibility
234 complex, class II, DQ beta 1.
235
236
237 **Declarations**

238 ***Acknowledgements:*** The authors would like to thank the Project MinE group and the ALS Variant
239 Server for sharing the summary statistics of GWAS on ALS.

240 ***Authors' contributions:*** X.C. and F.F. contributed to the conception and design of the study; X.C.,
241 X.S., X.Z., and Y.Z. contributed to acquisition and analyses of data; X.C., X.S., X.Z.,Y.Z., and F.F.
242 contributed to drafting and revising the manuscript.

243 ***Funding:*** This project is supported by the Science, Technology and Innovation Bureau of Baoan
244 (Grant No.: 2020JD445), the Science, Technology and Innovation Council of Shenzhen (Grant No.:
245 JCYJ20190809152801661), the National Natural Science Foundation of China (Grant No.:
246 82001652), the Shenzhen Key Medical Discipline Construction Fund (Grant No.: SZXK028), the
247 Swedish Research Council (Grant No.: 2019-01088) and Karolinska Institutet (Senior Researcher
248 Award and Strategic Research Area in Epidemiology).

249 ***Availability of data and materials:*** GWAS summary statistics of ALS were accessed from the
250 Project MinE group (https://www.projectmine.com/research/download-data) and the ALS Variant
251 Server (http://als.umassmed.edu).

252 ***Ethics approval and consent to participate:*** Because GWAS summary statistics rather than
253 individual-level data were used in this study, both informed consent and ethical approval were
254 waived according to the ethical review board in Shenzhen Baoan Women's and Children's Hospital.

255 ***Consent for publication:*** Not applicable.

256 ***Competing interests:*** The authors declare that they have no competing interests.

257

258

259 ## References

260 1. Beers DR, Appel SH: Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging
261 therapies. Lancet Neurol 2019, 18:211-220.

262 2. Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, Fang F: Peripheral immune
263 biomarkers and neurodegenerative diseases: A prospective cohort study with 20 years of follow-up.
264 Ann Neurol 2019, 86:913-926.

265 3. Vandenbroucke JP, Broadbent A, Pearce N: Causality and causal inference in epidemiology: the need for
266 a pluralistic approach. Int J Epidemiol 2016, 45:1776-1786.

267 4. Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F: Polygenic link between blood lipids and amyotrophic
268 lateral sclerosis. Neurobiol Aging 2018, 67: e201-e206.

269 5. Bandres-Ciga S, Noyce AJ, Hemani G, Nicolas A, Calvo A, Mora G, Consortium I, International ALSGC,
270 Tienari PJ, Stone DJ, et al: Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis.
271 Ann Neurol 2019, 85:470-481.

272 6. Zhan Y, Fang F: Smoking and amyotrophic lateral sclerosis: A mendelian randomization study. Ann
273 Neurol 2019, 85:482-484.

274 7. Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, Swaminathan B, Plomp R, Dekkers G, Ajore R, Ali
275 M, Bentlage AEH, Elmer E, et al: Identification of sequence variants influencing immunoglobulin levels.
276 Nat Genet 2017, 49:1182-1191.

277 8. van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, Vosa U,
278 de Jong S, Robinson MR, et al: Genome-wide association analyses identify new risk variants and the
279 genetic architecture of amyotrophic lateral sclerosis. Nat Genet 2016, 48:1043-1048.

280 9. Nicolas A, Kenna KP, Renton AE, Ticozzi N, Faghri F, Chia R, Dominov JA, Kenna BJ, Nalls MA, Keagle P, et
281 al: Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 2018, 97:1268-1283.

282 10. Euesden J, Lewis CM, O'Reilly PF: PRSice: Polygenic Risk Score software. Bioinformatics 2015, 31:1466-
283 1468.

284 11. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon
285 R, et al: The MR-Base platform supports systematic causal inference across the human phenome. Elife
286 2018, 7:e34408.

287 12. Armon C: Smoking is a cause of amyotrophic lateral sclerosis. High low-density lipoprotein cholesterol
288 levels? Unsure. Ann Neurol 2019, 85:465-469.

289 13. Molteni M, Rossetti C: Neurodegenerative diseases: The immunological perspective. J Neuroimmunol
290 2017, 313:109-115.

291 14. Novellino F, Sacca V, Donato A, Zaffino P, Spadea MF, Vismara M, Arcidiacono B, Malara N, Presta I,
292 Donato G: Innate Immunity: A Common Denominator between Neurodegenerative and
293 Neuropsychiatric Diseases. Int J Mol Sci 2020, 21(3):1115.

294 15. Sabatino JJ, Jr., Probstel AK, Zamvil SS: B cells in autoimmune and neurodegenerative central nervous
295 system diseases. Nat Rev Neurosci 2019, 20:728-745.

296 16. Chen K, Magri G, Grasset EK, Cerutti A: Rethinking mucosal antibody responses: IgM, IgG and IgD join
297 IgA. Nat Rev Immunol 2020,20(7):427-441.

298 17. Donnenfeld H, Kascsak RJ, Bartfeld H: Deposits of IgG and C3 in the spinal cord and motor cortex of ALS
299 patients. J Neuroimmunol 1984, 6(1):51-57.

300 18. Duarte F, Binet S, Lacomblez L, Bouche P, Preud'homme JL, Meininger V: Quantitative analysis of
301 monoclonal immunoglobulins in serum of patients with amyotrophic lateral sclerosis. J Neurol Sci 1991,
302 104(1):88-91.

303 19. May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, Brüning T, Pesch B, Stephan C,
304 Woitalla D, et al: Highly immunoreactive IgG antibodies directed against a set of twenty human proteins
305 in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS One 2014,
306 9(2):e89596.

307 20. Crayle J, Elmallah M, Sleasman J, Bedlack R: Total serum immunoglobulin A in ALS. Amyotroph Lateral
308 Scler Frontotemporal Degener 2020,22(1-2):61-65.

309 21. Watson N, Ding B, Zhu X, Frisina RD: Chronic inflammation - inflammaging - in the ageing cochlea: A
310 novel target for future presbycusis therapy. Ageing Res Rev 2017, 40:142-148.

311 22. Choi YR, Kang SJ, Kim JM, Lee SJ, Jou I, Joe EH, Park SM: FcgammaRIIB mediates the inhibitory effect of
312 aggregated alpha-synuclein on microglial phagocytosis. Neurobiol Dis 2015, 83:90-99.

313 23. Hallberg P, Smedje H, Eriksson N, Kohnke H, Daniilidou M, Ohman I, Yue QY, Cavalli M, Wadelius C,
314 Magnusson PKE, et al: Pandemrix-induced narcolepsy is associated with genes related to immunity and
315 neuronal survival. EBioMedicine 2019, 40:595-604.

316 **Figure 1. Illustration of the Mendelian randomization analysis**

317 Mendelian randomization analysis utilizes the instrumental variable method to infer the causality
318 between exposure and outcome. Because alleles are randomly assigned during mitosis, restricted
319 single nucleotide polymorphisms (SNPs) could be used as instrumental variables to test the causal
320 effect of exposure on the outcome.

321

322

323 **Figure 2. Polygenic risk score analyses between serum immunoglobulins and ALS**

324 Standardized polygenic risk scores based on the alleles increasing each type of immunoglobulin
325 (base trait) are used to predict ALS (target trait). X axis: independent SNPs are extracted from the
326 GWAS of base trait and then included in 100000 quantiles with gradually increasing P-value
327 thresholds (P_T, ranging from 0 to 1.0×10^{-6}, in steps of 1.0×10^{-11} per quantile). The P_T of the quantile
328 that explained the largest variance of the target is defined as the best-fitted P_T. Ten out of 100000
329 quantiles (including the best-fitted quantile) are presented. Y axis: Nagelkerke r^2, the proportion of
330 the target variation explained by independent SNPs in the P-threshold quantile.

331

332

333 **Figure 3. Mendelian randomization analyses between serum immunoglobulins and ALS**

334 Causal inference is performed by Mendelian randomization analysis, using the instrumental variable
335 method. It is primarily examined by the inverse variance weighted (IVW) method and
336 complemented with four other instrumental variable methods (MR Egger regression, weighted
337 median, simple mode, and weighted mode) as sensitivity analyses. X axis: SNP effect on the
338 exposure trait. Y axis: SNP effect on the outcome trait.

339

Table 1. SNPs used as instrumental variables for serum immunoglobulins in the MR analyses

	SNP (IV)	Position (hg 38)	Gene	EA	OA	Beta	SE	P-value
IgA	rs35668054	Chr2:71827707	*CYP26B1*	T	C	-0.18	0.02	1.60×10^{-20}
	rs968567	Chr11:61828092	*FADS2*	T	C	0.12	0.01	1.30×10^{-17}
	rs9276244	Chr6:32733444	*HLA-DQA2*	G	A	0.09	0.01	2.50×10^{-14}
	rs1071888	Chr22:29841373	*ASCC2*	A	T	-0.08	0.01	3.20×10^{-10}
	rs10065637	Chr5:56143024	*ANKRD55*	T	C	-0.08	0.01	5.00×10^{-10}
	rs142973694	Chr6: 31395164	*MICA*	A	G	0.13	0.02	6.70×10^{-10}
IgM	rs2511713	Chr8:102565637	*ODF1*	G	A	-0.13	0.01	1.70×10^{-24}
	rs735665	Chr11:123490689	*GRAMD1B*	A	G	0.15	0.01	1.00×10^{-23}
	rs6037651	Chr20:3705789	*SIGLEC1*	C	T	-0.09	0.01	2.90×10^{-15}
	rs617119	Chr3:32414275	*CMTM7*	C	T	-0.09	0.01	1.10×10^{-14}
	rs11651596	Chr17:39899863	*GSDMB*	C	T	-0.09	0.01	2.30×10^{-14}
IgG	rs7554873	Chr1:161642443	*FCGR2B*	C	T	-0.28	0.02	8.90×10^{-32}
	rs2133037	Chr6:32699819	*HLA-DQB1*	A	G	-0.19	0.02	2.40×10^{-14}

EA=effect allele; OA=other allele; SE=standard error, which was calculated by using P-value and sample size; P-value=association P-value.

340

Table 2. Polygenic associations between serum immunoglobulins and ALS in the PRS analyses

Base	Target	Best-fitted P_T	n_{SNP}	OR	SE	r^2 (%)	P-value
IgA	ALS_2016	8.6000×10^{-10}	54	0.861	0.032	0.059	4.2×10^{-6}
	ALS_2018	7.0001×10^{-7}	43	0.948	0.031	0.004	0.085
IgM	ALS_2016	4.8000×10^{-10}	47	0.905	0.032	0.028	0.002
	ALS_2018	3.5010×10^{-8}	42	1.051	0.028	0.004	0.074
IgG	ALS_2016	5.1001×10^{-7}	49	1.181	0.033	0.069	5.9×10^{-7}
	ALS_2018	5.7001×10^{-7}	22	1.130	0.036	0.014	0.001

PRS=polygenic risk score; ALS=amyotrophic lateral sclerosis; Best-fitted P_T=association P-value threshold of the quantile that explained the largest variance of the target; n_{SNP}=numbers of independent single nucleotide polymorphisms (SNPs) included in the best-fitted quantile; OR: odds ratio per standard deviation of genetically determined level for each type of serum immunoglobulin; SE=standard error; r^2= the proportion of the target variation explained by SNPs in the best-fitted quantile.

341

Table 3. Comparison of results from different methods in Mendelian randomization analyses

Exposure	Method	NIV	ALS_2016			ALS_2018		
			OR	SE	Pval	OR	SE	Pval
IgA	IVW	6	0.968	0.022	0.148	0.880	0.100	0.201
	MR Egger	6	1.126	0.067	0.152	1.477	0.303	0.267
	Weighted median	6	0.979	0.025	0.382	0.927	0.105	0.466
	Simple mode	6	0.990	0.035	0.783	1.033	0.180	0.866
	Weighted mode	6	0.991	0.030	0.774	1.008	0.152	0.960
IgM	IVW	5	0.996	0.015	0.787	1.031	0.060	0.617
	MR Egger	5	0.962	0.070	0.619	0.873	0.279	0.661
	Weighted median	5	0.990	0.019	0.575	1.003	0.073	0.965
	Simple mode	5	0.992	0.025	0.753	0.997	0.096	0.979
	Weighted mode	5	0.990	0.022	0.708	0.997	0.089	0.978
IgG	IVW	2	**1.056**	**0.021**	**0.009**	1.073	0.087	0.420

NIV=numbers of independent SNPs used as instrumental variables; IVW= inverse variance weighted method; OR: odds ratio per standard deviation of genetically determined level for each type of serum immunoglobulin; SE=standard error; Pval=P-value for the causal inference, significance is defined as Pval<0.05.

342


Confounders
(Unmeasured factors)
Instrumental
Variables
(e.g., SNPs)
Exposure
(e.g., IgG)
Outcome
(e.g., ALS)

Discovery phase:







Replication phase:







Discovery phase:

IgA and ALS_2016



IgM and ALS_2016



IgG and ALS_2016



Replication phase:

IgA and ALS_2018



IgM and ALS_2018



IgG and ALS_2018